Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2021; 12(5): 603-615
Published online May 15, 2021. doi: 10.4239/wjd.v12.i5.603
Published online May 15, 2021. doi: 10.4239/wjd.v12.i5.603
Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes
William de Jesús Ríos-Ríos, Honorio Torres-Aguilar, Department of Biochemical Sciences Faculty, Universidad Autónoma “Benito Juárez” de Oaxaca, Oaxaca 68120, Mexico
Sorely Adelina Sosa-Luis, Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City 07360, Mexico
Author contributions: All authors contributed to the writing of the manuscript; Torres-Aguilar H supervised the project and generated the final version of the paper.
Supported by A basic science grant from CONACyT , No. 285480 ; and the Department of Clinical Immunology Research of the Biochemical Sciences Faculty.
Conflict-of-interest statement: The authors have declared having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Honorio Torres-Aguilar, PhD, Professor, Department of Biochemical Sciences Faculty, Universidad Autónoma “Benito Juárez” de Oaxaca, Av. Universidad S/N Ex-Hacienda 5 Señores, Oaxaca 68120, Mexico. qbhonorio@hotmail.com
Received: January 21, 2021
Peer-review started: January 21, 2021
First decision: February 25, 2021
Revised: February 26, 2021
Accepted: April 20, 2021
Article in press: April 20, 2021
Published online: May 15, 2021
Processing time: 105 Days and 9.4 Hours
Peer-review started: January 21, 2021
First decision: February 25, 2021
Revised: February 26, 2021
Accepted: April 20, 2021
Article in press: April 20, 2021
Published online: May 15, 2021
Processing time: 105 Days and 9.4 Hours
Core Tip
Core Tip: Autoimmunity in type 1 diabetes (T1D) is severe and leads to pancreatic dysfunction; therefore, therapies that can lessen this process are required. Cell therapy with tolerogenic dendritic cells (tolDCs) is a promising strategy. Various protocols have been implemented for tolDC generation, using stimuli such as cytokines, growth factors, and drugs. These cells are also subjected to treatments with antisense oligonucleotides, liposomes, toll-like receptor ligands, and peptides of the pancreatic islets, for optimization as T1D immunotherapy. Preclinical and clinical trials have demonstrated effectiveness of tolDC-based therapy. This review aims to give a detailed understanding of current advances in tolDC-based T1D treatment.